Summit Therapeutics

Summit Therapeutics, Inc. is a biopharmaceutical company focused on oncology, dedicated to discovering, developing, and commercializing therapies that benefit patients, physicians, caregivers, and society. Founded in 2003 and headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK, the company is listed on the Nasdaq Global Market under the symbol 'SMMT'. The company employs a comprehensive approach to drug development, which includes designing and executing clinical trials and obtaining regulatory approvals. Summit Therapeutics collaborates with various institutions to advance its product pipeline, which includes key candidates like Ivonescimab, a bispecific antibody for non-small cell lung cancer, Ridinilazole for C. difficile infections, and treatments for carbapenem-resistant enterobacteriaceae (CRE) infections. With a team of around 159 professionals, Summit Therapeutics is committed to addressing serious unmet medical needs and improving the quality of life for patients.